The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of December 31, 2017:
- 36 negotiations are currently underway with 5 new files added since the last update of November 30, 2017:
- Blincyto (blinatumomab) : Used to treat adult acute lymphoblastic leukemia
- Blincyto (blinatumomab) : Used to treat pediatric acute lymphoblastic leukemia
- Caprelsa (vandetanib) : Used to treat medullary thyroid cancer
- Lancora (ivabradine) : Used to treat NYHA class II or III heart failure
- Ocaliva (obeticholic acid) : Used to treat primary biliary cholangitis
- 196 joint negotiations have been completed with 8 new files added since the last update of November 30, 2017:
- Cosentyx (secukinumab) : Used to treat psoriatic arthritis
- Cosentyx (secukinumab) : Used to treat ankylosing spondylitis
- Ibrance (palbociclib) : Used to treat advanced breast cancer
- Kyprolis (carfilzomib) : Used to treat multiple myeloma
- Kyprolis (carfilzomib) : Used to treat multiple myeloma (relapsed)
- Ravicti (glycerol phenylbutyrate) : Used to treat urea cycle disorders
- Taltz (Ixekizumab) : Used to treat moderate to severe plaque psoriasis
- Uptravi (selexipag) : Used to treat pulmonary arterial hypertension
- 57 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with 1 new file added since the last update of November 30, 2017:
- Rituxan (rituximab) : Used to treat acute lymphoblastic leukemia
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of November 30, 2017.
For more information, please consult the pCPA’s website.